Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
3.050
-0.060 (-1.93%)
Dec 20, 2024, 4:00 PM EST - Market closed
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $115.18M in the quarter ending September 30, 2024, with 6.12% growth. This brings the company's revenue in the last twelve months to $455.04M, up 1.34% year-over-year. In the year 2023, Organogenesis Holdings had annual revenue of $433.14M, down -3.94%.
Revenue (ttm)
$455.04M
Revenue Growth
+1.34%
P/S Ratio
0.89
Revenue / Employee
$527,886
Employees
862
Market Cap
404.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2001 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tactile Systems Technology | 285.05M |
| Akebia Therapeutics | 169.88M |
| National Research | 144.16M |
| Quanterix | 129.33M |
| Personalis | 87.49M |
| Nano-X Imaging | 10.68M |
| IGM Biosciences | 2.92M |
| Allogene Therapeutics | 43.00K |
ORGO News
- 4 weeks ago - Organogenesis Expands Manufacturing Capacity to Support Future Growth - GlobeNewsWire
- 5 weeks ago - Organogenesis Commends Final LCDs - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock - GlobeNewsWire
- 5 weeks ago - Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis - GlobeNewsWire
- 2 months ago - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 - GlobeNewsWire
- 2 months ago - Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers - GlobeNewsWire
- 3 months ago - Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September - GlobeNewsWire